Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results

After reviewing the trial’s Independent Data Monitoring Committee, the EMPA-KIDNEY trial announced it would stop early as it met prespecified criteria for positive efficacy. The trial, which involves authorities from the University of Oxford, Boehringer Ingelheim and Eli Lilly and Company, has evaluated the efficacy and safety of therapeutic empagliflozin in adults with chronic kidney disease (CKD).